Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications
出版年份 2017 全文链接
标题
Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 6, Pages 1182
出版商
MDPI AG
发表日期
2017-06-02
DOI
10.3390/ijms18061182
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway
- (2017) Hongyu Shen et al. GENE
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
- (2017) Wen-Zhao Lin et al. Breast Cancer
- MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1
- (2017) Qing Xie et al. Oncotarget
- Research needs in breast cancer
- (2016) F. Cardoso et al. ANNALS OF ONCOLOGY
- Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling
- (2016) Xin Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells
- (2016) Xinfeng Yu et al. BIOMEDICINE & PHARMACOTHERAPY
- A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
- (2016) Nadia Harbeck et al. BREAST CANCER RESEARCH AND TREATMENT
- Generic oncology drugs: are they all safe?
- (2016) Y Tony Yang et al. LANCET ONCOLOGY
- Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy
- (2016) Zhen-Ru Liu et al. LIFE SCIENCES
- MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
- (2016) L Venturutti et al. ONCOGENE
- MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway
- (2016) Xiaohui Zhang et al. PLoS One
- Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression
- (2016) Jiang Zhu et al. Cell Death & Disease
- A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
- (2016) F. Du et al. Scientific Reports
- MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel
- (2015) He-da Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin
- (2015) Jianxin Lv et al. BIOMEDICINE & PHARMACOTHERAPY
- Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4
- (2015) Aamir Ahmad et al. BMC CANCER
- MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells
- (2015) Shanliang Zhong et al. GENE
- Decrease of Let-7f in Low-Dose Metronomic Paclitaxel Chemotherapy Contributed to Upregulation of Thrombospondin-1 in Breast Cancer
- (2015) Wei-Yang Tao et al. International Journal of Biological Sciences
- MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy
- (2015) Xinfeng Yu et al. Molecular Cancer
- Towards a molecular understanding of microRNA-mediated gene silencing
- (2015) Stefanie Jonas et al. NATURE REVIEWS GENETICS
- miR-520h is crucial for DAPK2 regulation and breast cancer progression
- (2015) C-M Su et al. ONCOGENE
- Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer
- (2015) J Niu et al. ONCOGENE
- miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression
- (2015) YA-SAI YAO et al. ONCOLOGY REPORTS
- MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer
- (2015) Zhen-Hua Wu et al. TUMOR BIOLOGY
- MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer
- (2015) Haifei He et al. TUMOR BIOLOGY
- Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer
- (2015) Zhiqiang Ye et al. TUMOR BIOLOGY
- MicroRNA-205 increases the sensitivity of docetaxel in breast cancer
- (2015) YANG CAI et al. Oncology Letters
- MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer
- (2015) Xiaoping Liu et al. Oncotarget
- miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response
- (2015) Alessandra Cataldo et al. Oncotarget
- Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR
- (2015) Baotong Zhang et al. Oncotarget
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
- (2015) Leticia De Mattos-Arruda et al. Oncotarget
- MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition
- (2015) Yuan Zhang et al. Scientific Reports
- A MicroRNA Expression Signature In Taxane-anthracycline-Based Neoadjuvant Chemotherapy Response
- (2015) Yi Zheng et al. Journal of Cancer
- Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line
- (2015) Xi Gu et al. MEDICAL SCIENCE MONITOR
- microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers
- (2015) Pierluigi Gasparini et al. Oncotarget
- miRNA expression patterns in chemoresistant breast cancer tissues
- (2014) Jianxin Lv et al. BIOMEDICINE & PHARMACOTHERAPY
- Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
- (2014) Xing-Ming Ye et al. BMC CANCER
- Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
- (2014) Hans-Joachim Lück et al. BREAST CANCER RESEARCH AND TREATMENT
- Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer
- (2014) S. T. Bailey et al. CANCER RESEARCH
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
- (2014) Claire Corcoran et al. Molecular Cancer
- Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial–mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells
- (2014) R L Carpenter et al. ONCOGENE
- MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer
- (2014) Mao Ouyang et al. PLoS One
- Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
- (2014) Qian Li et al. PLoS One
- MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells
- (2014) Qing Hu et al. TUMOR BIOLOGY
- MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
- (2014) Xiao He et al. TUMOR BIOLOGY
- Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs
- (2014) Wei-xian Chen et al. TUMOR BIOLOGY
- Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
- (2013) Lucia Del Mastro et al. BMC CANCER
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
- (2013) Reiner Hoppe et al. EUROPEAN JOURNAL OF CANCER
- Chemotherapy regimens in early breast cancer: major controversies and future outlook
- (2013) Markus Joerger et al. Expert Review of Anticancer Therapy
- miR-222 and miR-29a contribute to the drug-resistance of breast cancer cells
- (2013) Shanliang Zhong et al. GENE
- The Overexpression of Hypomethylated miR-663 Induces Chemotherapy Resistance in Human Breast Cancer Cells by Targeting Heparin Sulfate Proteoglycan 2 (HSPG2)
- (2013) Haiyan Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer
- (2013) Zhongzhen Guan et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
- (2013) Helena M Earl et al. LANCET ONCOLOGY
- 5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells
- (2013) YONGSHAN YAO et al. Oncology Letters
- The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer
- (2012) Rabia A. Gilani et al. BREAST CANCER RESEARCH AND TREATMENT
- Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials
- (2012) Wei-Xiang Qi et al. CURRENT MEDICAL RESEARCH AND OPINION
- Chemotherapy-Resistant Metastatic Breast Cancer
- (2012) Carrie Marquette et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies
- (2012) Lidia Rita Corsini et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells
- (2012) Kezhen Lv et al. PLoS One
- Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
- (2012) Thuy Vu et al. Frontiers in Oncology
- miRNA-34a is associated with docetaxel resistance in human breast cancer cells
- (2011) L. Kastl et al. BREAST CANCER RESEARCH AND TREATMENT
- Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
- (2011) Eun-Jung Jung et al. CANCER
- Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
- (2011) Maurizio Belfiglio et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
- (2011) Françoise Rothé et al. PLoS One
- MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
- (2010) F. Germán Rodríguez-González et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin
- (2010) Igor P. Pogribny et al. INTERNATIONAL JOURNAL OF CANCER
- MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression
- (2010) Ming Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
- (2010) X Rao et al. ONCOGENE
- MicroRNA Regulation of DNA Repair Gene Expression in Hypoxic Stress
- (2009) M. E. Crosby et al. CANCER RESEARCH
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer
- (2009) Francisco J. Esteva et al. Nature Reviews Clinical Oncology
- Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
- (2008) Wing Pui Tsang et al. APOPTOSIS
- Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
- (2008) O. Kovalchuk et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now